Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance

被引:36
作者
Schmidt, B
Walter, H
Moschik, B
Paatz, C
van Vaerenbergh, K
Vandamme, AM
Schmitt, M
Harrer, T
Überla, K
Korn, K
机构
[1] Univ Erlangen Nurnberg, German Natl Referenc Ctr Retroviruses, Inst Clin & Mol Virol, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Clin Immunol, Dept Med 3, D-91054 Erlangen, Germany
[3] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[4] Univ Leipzig, Inst Virol, Leipzig, Germany
关键词
HIV; antiretroviral therapy; protease inhibitors; resistance; cross-resistance;
D O I
10.1097/00002030-200008180-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Resistance against protease inhibitors (PI) can either be analysed genotypically or phenotypically. However, the interpretation of genotypic data is difficult, particularly for PI, because of the unknown contributions of several mutations to resistance and cross-resistance. Objective: Development of an algorithm to predict PI phenotype from genotypic data. Methods: Recombinant viruses containing patient-derived protease genes were analysed for sensitivity to indinavir, saquinavir, ritonavir and nelfinavir. Drug resistance-associated mutations were determined by direct sequencing, geno- and phenotypic data were compared for 119 samples from 97 HIV-1 infected patients. Results: Samples with one or two mutations in the gene for the protease were phenotypically sensitive in 74.3%, whereas 83.6% of samples with five or more mutations were resistant against all PI tested. Some mutations (361, 63P, 71V/T, 771) were frequent both in sensitive and resistant samples, whereas others (241, 30N, 461/L, 48V, 54V, 82A/F/T/S, 84V, 90M) were predominantly present in resistant samples. Therefore, the presence or absence of a single drug resistance-associated mutation predicted phenotypic PI resistance with high sensitivity (96.5-100%) but low specificity (13.3-57.4%). A more specific algorithm was obtained by taking into account the total number of drug resistance-associated mutations in the gene for the protease and restricting these to certain key positions for the PI. The algorithm was subsequently validated by analysis of 72 independent samples. Conclusion: With an optimized algorithm, phenotypic PI resistance can be predicted by viral genotype with good sensitivity (89.1-93.0%) and specificity (82.6-93.3%). The reliability and relevance of this algorithm should be further evaluated in clinical practice. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:1731 / 1738
页数:8
相关论文
共 29 条
[1]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[2]   HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy [J].
Craig, C ;
Race, E ;
Sheldon, J ;
Whittaker, L ;
Gilbert, S ;
Moffatt, A ;
Rose, J ;
Dissanayeke, S ;
Chirn, GW ;
Duncan, IB ;
Cammack, N .
AIDS, 1998, 12 (13) :1611-1618
[3]   Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure [J].
Deeks, SG ;
Grant, RM ;
Beatty, GW ;
Horton, C ;
Detmer, J ;
Eastman, S .
AIDS, 1998, 12 (10) :F97-F102
[4]   Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors [J].
Dulioust, A ;
Paulous, S ;
Guillemot, L ;
Delavalle, AM ;
Boué, F ;
Clavel, F .
JOURNAL OF VIROLOGY, 1999, 73 (01) :850-854
[5]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199
[6]   Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monotherapy [J].
Eastman, PS ;
Mittler, J ;
Kelso, R ;
Gee, C ;
Boyer, E ;
Kolberg, J ;
Urdea, M ;
Leonard, JM ;
Norbeck, DW ;
Mo, HM ;
Markowitz, M .
JOURNAL OF VIROLOGY, 1998, 72 (06) :5154-5164
[7]   HIV-protease inhibitors [J].
Flexner, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1281-1292
[8]   Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. -: J Antimicrob Chemother 1998; 42:269-270 [J].
Vahaboglu, H ;
Saribas, S ;
Akbal, H ;
Ozturk, R ;
Yucel, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :269-270
[9]   Nelfinavir - A review of its therapeutic efficacy in HIV infection [J].
Jarvis, B ;
Faulds, D .
DRUGS, 1998, 56 (01) :147-167
[10]   RECOMBINANT VIRUS ASSAY - A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
KELLAM, P ;
LARDER, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :23-30